

## Agneta Wennerholm joins Pharmability as Consulting Clinical Project Manager

Pharmability, a biotechnology company developing next-generation treatments for autoimmune skin diseases, today announced the appointment of Agneta Wennerholm as Clinical Project Manager. The appointment supports the company's preparations for the clinical development of TIR-C, a novel immunomodulatory drug candidate for the treatment of atopic dermatitis (eczema).



Agneta Wennerholm brings more than 25 years of experience in clinical development across pharmaceutical and biotechnology companies and clinical CROs in a broad range of therapeutic areas. She has a long track record working with Swedish biotech companies in early-phase clinical trials.

“We are very pleased to welcome Agneta to Pharmability. Her extensive experience in clinical project management and early-phase development strengthens our capacity as we advance TIR-C into its next stage of development and continue building a strong and experienced project team,” says Leo Holmgren, CEO of Pharmability.

As TIR-C is prepared for clinical studies in its first indication, the company is entering a key stage of development that requires both strategic and operational execution.

Agneta will lead the company's clinical development activities and support preparations for the upcoming first-in-human clinical trial, working closely with internal teams and external partners to ensure efficient, high-quality execution.

**For more information, please contact:**

Leo Holmgren, CEO

Phone: Tfn: +46 70 049 18 42

Email: [leo.holmgren@pharmability.com](mailto:leo.holmgren@pharmability.com)

**About Pharmability**

Pharmability (formerly TIRmed Pharma) is a biotechnology company developing next-generation immunomodulatory therapies for autoimmune skin diseases, with an initial focus on atopic dermatitis (eczema). The company's drug candidate, TIR-C, is a topical oligonucleotide-based treatment that regulates immune responses and targets the disease's underlying mechanisms. Promising preclinical results support its potential to provide long-lasting relief while reducing treatment burden. Building on expertise in immunology and drug development, the company is pioneering new solutions in dermatological immunotherapy to enable more targeted and effective treatment options.

Pharmability is headquartered in Stockholm, Sweden. For more information, visit [pharmability.com](https://pharmability.com) and follow Pharmability on [LinkedIn](#).